Chapter
Emerging Business Models for Pharma and Biotech
1:22:43 - 1:29:13 (06:29)
Companies in the pharma and biotech industry are adopting novel business models that allow them to play a more significant role in drug development outcomes, rather than simply paying for a service or software license. The trend is moving towards backend revenue sharing and royalty arrangements rather than upfront seat licenses.
Clips
The traditional seat-based pricing model may not be the most effective way to price tech products and services, and companies should reconsider alternative pricing strategies for their offerings.
1:22:43 - 1:25:02 (02:19)
Summary
The traditional seat-based pricing model may not be the most effective way to price tech products and services, and companies should reconsider alternative pricing strategies for their offerings.
ChapterEmerging Business Models for Pharma and Biotech
EpisodeE112: Is Davos a grift? Plus: globalist mishaps, debt ceilings, TikTok's endgame & more
PodcastAll-In with Chamath, Jason, Sacks & Friedberg
Companies are emerging in the pharma and biotech industries that participate in drug development outcomes rather than just charging fees for services, such as Royalty Pharma.
1:25:02 - 1:27:28 (02:25)
Summary
Companies are emerging in the pharma and biotech industries that participate in drug development outcomes rather than just charging fees for services, such as Royalty Pharma. Giving away top of the funnel tasks to AI machines in exchange for backend rev share can help improve outcomes.
ChapterEmerging Business Models for Pharma and Biotech
EpisodeE112: Is Davos a grift? Plus: globalist mishaps, debt ceilings, TikTok's endgame & more
PodcastAll-In with Chamath, Jason, Sacks & Friedberg
The open source community has the potential to create profitable businesses through forking and verticalizing projects towards specialized niches, such as AI testing.
1:27:28 - 1:29:13 (01:44)
Summary
The open source community has the potential to create profitable businesses through forking and verticalizing projects towards specialized niches, such as AI testing. While there's still room for experimentation, the potential for growth is impressive.